Syntropic Medical GmbH

Syntropic Medical is pioneering a revolutionary approach to mental health treatment through non-invasive light-based neuromodulation. Founded in 2023 as a spin-out from the Institute of Science and Technology Austria (ISTA), the company is transforming how depression is treated by harnessing the brain's innate healing capacity. Their breakthrough technology delivers precise 60 Hz light stimulation through the eyes, activating microglia - the brain's immune cells - to reshape neural connections and promote neuroplasticity. This novel mechanism addresses a critical unmet need: traditional antidepressants fail for millions of patients, with approximately 70% experiencing inadequate relief. Syntropic's approach enables faster therapeutic effects compared to pharmaceutical options, which typically require 2-3 weeks to take effect.

The company has rapidly advanced from lab discovery to clinical trials in just 18 months, demonstrating their focused execution. Syntropic's technology is based on pioneering research by scientific co-founders Prof. Sandra Siegert and Dr. Alessandro Venturino at ISTA. Their team combines deep expertise in neuroscience, medical device innovation, and clinical development. Currently, the company is conducting two clinical studies: the LUX Study in Brazil and the NEON Study at NYU Langone Health. Syntropic Medical has raised early-stage funding from investors including xista science ventures and AWS, positioning them to advance their mission of making effective mental health solutions more accessible to those who need them most.